Human Papillomavirus Type 45 L1 Protein Vaccine
The L1 Protein, Human Papillomavirus Type 45 Vaccine is a subunit component of the HPV vaccine that targets HPV type 45, a high-risk strain associated with cervical, anal, and other cancers. It consists of virus-like particles (VLPs) made from the L1 capsid protein, which stimulates immune protection against HPV type 45 infection. This component is included in multivalent HPV vaccines (such as Gardasil 9) to provide broad protection against multiple HPV strains.
A vaccine component that provides immunity against high-risk HPV type 45 to prevent related cancers.
Key facts at a glance
- RxNorm
- 1596932
- Generic
- L1 Protein, Human Papillomavirus Type 45 Vaccine
- Class
- unclassified
- Brands
- Gardasil 9
- Availability
- rx
- Lactation
- unknown
- Routes
- —
- Forms
- prefilled syringe, injection
- Regions
- US, EU, CN, JP
- Monitoring
- —
This page is for informational purposes only.
Do not use this information to diagnose yourself or to replace a physician's advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication. If you believe you are experiencing a medical emergency, call your local emergency number immediately.
Prevention of infection and related diseases caused by Human Papillomavirus Type 45, including cervical, anal, vulvar, vaginal, and oropharyngeal cancers. Typically administered as part of a broader multivalent HPV vaccine formulation.
The L1 capsid protein is expressed as virus-like particles (VLPs) that structurally mimic the native HPV virus. These VLPs induce neutralizing antibodies against HPV type 45 without containing infectious viral DNA, providing prophylactic immunity against future infection.
This is a prophylactic vaccine component; it does not treat existing HPV infections or HPV-related diseases. Most effective when administered before sexual debut. Part of multivalent formulations (Gardasil 9 includes types 6, 11, 16, 18, 31, 33, 45, 52, 58). Standard vaccination series recommended for adolescents aged 11-12 years, with catch-up vaccination through age 26.
Official drug label
WellAlly may earn a referral fee from linked resources at no extra cost to you. Editorial content is never influenced by commercial relationships.
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 29, 2026. · Read our editorial policy